New Results from an Interim Phase 1 Study Evaluating Nucresiran (ALN-TTRsc04) Presented at the American Heart Association (AHA) Scientific Sessions 2024

17 Nov, 2024 New Results from an Interim Phase 1 Study Evaluating Nucresiran (ALN-TTRsc04) Presented at the American Heart Association (AHA) Scientific Sessions 2024

Results from the interim Phase 1 study of nucresiran (ALN-TTRsc04), an investigational next-generation RNAi therapeutic for the treatment of transthyretin amyloidosis, were presented at the American Heart Association (AHA) Scientific Sessions 2024.

Murad et al. “A Phase 1, Single Ascending Dose Study to Evaluate ALN-TTRsc04, a Next-Generation RNA Interference Therapeutic, in Healthy Participants for Potential Treatment of Transthyretin Amyloidosis”